AU2013346624B2 - Quick-acting insulin formulation including a substituted anionic compound - Google Patents

Quick-acting insulin formulation including a substituted anionic compound Download PDF

Info

Publication number
AU2013346624B2
AU2013346624B2 AU2013346624A AU2013346624A AU2013346624B2 AU 2013346624 B2 AU2013346624 B2 AU 2013346624B2 AU 2013346624 A AU2013346624 A AU 2013346624A AU 2013346624 A AU2013346624 A AU 2013346624A AU 2013346624 B2 AU2013346624 B2 AU 2013346624B2
Authority
AU
Australia
Prior art keywords
compound
insulin
function
chosen
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013346624A
Other languages
English (en)
Other versions
AU2013346624A1 (en
Inventor
Richard Charvet
Emmanuel DAUTY
Gerard Soula
Olivier Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1260808A external-priority patent/FR2997952B1/fr
Priority claimed from FR1260855A external-priority patent/FR2997857B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Publication of AU2013346624A1 publication Critical patent/AU2013346624A1/en
Priority to AU2018208773A priority Critical patent/AU2018208773B2/en
Application granted granted Critical
Publication of AU2013346624B2 publication Critical patent/AU2013346624B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2013346624A 2012-11-13 2013-11-13 Quick-acting insulin formulation including a substituted anionic compound Active AU2013346624B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018208773A AU2018208773B2 (en) 2012-11-13 2018-07-30 Quick-acting insulin formulation including a substituted anionic compound

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201261725775P 2012-11-13 2012-11-13
US61/725,775 2012-11-13
FR12/60808 2012-11-13
FR1260808A FR2997952B1 (fr) 2012-11-13 2012-11-13 Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
US201261726349P 2012-11-14 2012-11-14
FR12/60855 2012-11-14
US61/726,349 2012-11-14
FR1260855A FR2997857B1 (fr) 2012-11-14 2012-11-14 Formulation a action rapide d'insuline comprenant un compose anionique substitue
PCT/FR2013/052736 WO2014076423A1 (fr) 2012-11-13 2013-11-13 Formulation à action rapide d'insuline comprenant un composé anionique substitué

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018208773A Division AU2018208773B2 (en) 2012-11-13 2018-07-30 Quick-acting insulin formulation including a substituted anionic compound

Publications (2)

Publication Number Publication Date
AU2013346624A1 AU2013346624A1 (en) 2015-05-14
AU2013346624B2 true AU2013346624B2 (en) 2018-08-09

Family

ID=50728493

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013346624A Active AU2013346624B2 (en) 2012-11-13 2013-11-13 Quick-acting insulin formulation including a substituted anionic compound
AU2018208773A Active AU2018208773B2 (en) 2012-11-13 2018-07-30 Quick-acting insulin formulation including a substituted anionic compound

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018208773A Active AU2018208773B2 (en) 2012-11-13 2018-07-30 Quick-acting insulin formulation including a substituted anionic compound

Country Status (18)

Country Link
US (6) US9700599B2 (enExample)
EP (2) EP2919804B1 (enExample)
JP (4) JP6322642B2 (enExample)
KR (3) KR20150082640A (enExample)
CN (2) CN104902922B (enExample)
AU (2) AU2013346624B2 (enExample)
BR (1) BR112015010799B1 (enExample)
CA (1) CA2889552C (enExample)
DK (1) DK2919804T3 (enExample)
EA (1) EA034393B1 (enExample)
ES (1) ES2670969T3 (enExample)
HK (1) HK1252137A1 (enExample)
IL (2) IL238446B (enExample)
MX (2) MX377292B (enExample)
PL (1) PL2919804T3 (enExample)
SA (1) SA515360428B1 (enExample)
WO (1) WO2014076423A1 (enExample)
ZA (2) ZA201503293B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014002986A2 (pt) 2011-08-10 2017-06-13 Adocia composição sob a forma de uma solução injetável, e formulação de dose única
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013104861A1 (fr) 2012-01-09 2013-07-18 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
EP2920200A1 (fr) * 2012-11-13 2015-09-23 Adocia Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
FR3020952B1 (fr) * 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (fr) 2014-05-14 2018-08-31 Adocia Composition aqueuse comprenant au moins une proteine et un agent solubilisant, sa preparation et ses utilisations
AR102869A1 (es) * 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
KR200487058Y1 (ko) 2016-08-08 2018-07-30 (주)포티스 색변 우산
WO2018153506A1 (en) 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt
GB201707189D0 (en) * 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
EA201992351A1 (ru) * 2017-06-01 2020-03-26 Эли Лилли Энд Компани Быстродействующие композиции инсулина
WO2019193353A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083984A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2387201A (en) 1942-01-12 1945-10-16 Bonneville Ltd Mono-acyl ethylene diamines
US2847385A (en) 1954-10-07 1958-08-12 Ohio Commw Eng Co Detergent-soil suspending composition containing carboxymethyl dextran
GB797959A (en) 1955-02-09 1958-07-09 Vitrum Apoteksvar Improvements in or relating to the preparation of insulin
JPS4722571U (enExample) 1971-03-09 1972-11-14
IT1053718B (it) 1973-04-04 1981-10-10 Zambeletti Spa L Metodo per prolungare l azione di farmaci attraverso la formazione di composti mcromolecolari
US4006059A (en) 1974-07-29 1977-02-01 Purdue Research Foundation Hydrophobic noncovalent binding of proteins to support materials
US4011137A (en) 1974-08-26 1977-03-08 Standard Brands Incorporated Process for producing dextrose using mixed immobilized enzymes
US4126628A (en) 1977-03-28 1978-11-21 Canadian Patents And Development Limited Acylation of amino acids
JPS53137911A (en) 1977-05-06 1978-12-01 Showa Denko Kk Preparation of n-(alpha-hydroxyalkanoyl)-peptides
SU727647A1 (ru) * 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4438029A (en) 1978-01-19 1984-03-20 Research Corporation Synthetic peptides
DE3064888D1 (en) 1979-04-30 1983-10-27 Hoechst Ag Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization
AU550068B2 (en) 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
FI78616C (fi) 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
DE3382112D1 (de) 1982-04-30 1991-02-21 Ajinomoto Kk Pharmazeutische zusammensetzung.
EP0160103B1 (en) 1983-10-26 1990-06-20 Kanebo, Ltd. Proteinous emulsifier, process for its preparation, and emulsified cosmetic preparation containing same
US4839341A (en) 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
JPS6112899A (ja) 1984-06-27 1986-01-21 Hitachi Metals Ltd 異種粒子を含む金属材料の電解研磨方法
JPS61176532A (ja) 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4873322A (en) * 1986-01-24 1989-10-10 Ciba-Geigy Corporation Saccharide derivatives and processes for their manufacture
PL149145B1 (en) 1986-12-17 1990-01-31 The method of obtaining of symmetrical diamides of citric acid
PT86819B (pt) 1987-02-25 1992-05-29 Novo Industri As Processo para a preparacao de novos derivados da insulina e de composicoes farmaceuticas que os contem
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DK111489D0 (da) 1989-03-08 1989-03-08 Novo Nordisk As Peptider
JPH03153653A (ja) 1989-11-10 1991-07-01 Kuraray Co Ltd Ｎ―（１―アルコキシカルボニルスチリル）フマルアミド酸およびその製造方法
DE69019534T2 (de) 1989-12-21 1995-09-21 Novonordisk As Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten.
CA2035248A1 (en) 1990-02-06 1991-08-07 Shang-Ren Wu Vinyl carbamate compounds and detergent compositions containing them
US6027565A (en) * 1991-02-25 2000-02-22 Bugg; Charles E. Method and apparatus for crystalizing macromolecules in microgravity
AU653026B2 (en) 1991-06-07 1994-09-15 Teikoku Seiyaku Kabushiki Kaisha Physiologically active polypeptide-containing pharmaceutical composition
US5204366A (en) 1991-06-10 1993-04-20 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents, compositions and method for use thereof
US5310937A (en) 1991-06-10 1994-05-10 American Cyanamid Company 2,5-dioxo-3-pyrroline-1-acetanilide fungicidal agents and method for the preparation thereof
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
JPH0782225A (ja) 1993-09-14 1995-03-28 Fuji Photo Film Co Ltd アミノ酸誘導体及びその用途
KR970007419B1 (ko) 1993-12-30 1997-05-08 한솔제지 주식회사 승화형 열전사 기록용 색소
JP3414539B2 (ja) 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5820881A (en) 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
WO1997017945A2 (en) 1995-11-13 1997-05-22 Minimed, Inc. Methods and compositions for the delivery of monomeric proteins
JP2757252B2 (ja) 1995-11-27 1998-05-25 工業技術院長 重合性糖エステル及びその製造方法
KR100236393B1 (ko) 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
AUPO066096A0 (en) 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
JP3991240B2 (ja) * 1997-03-10 2007-10-17 東洋紡績株式会社 スフィンゴ糖脂質合成用高分子プライマーおよびその用途
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
FR2781485B1 (fr) 1998-07-21 2003-08-08 Denis Barritault Polymeres biocompatibles leur procede de preparation et les compositions les contenant
US6991798B1 (en) 1998-08-07 2006-01-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2624400A (en) 1999-01-26 2000-08-07 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
AU3841500A (en) 1999-04-22 2000-11-10 Sankyo Company Limited Resin-bearing ketoamides and process for the preparation thereof
JP2003514014A (ja) 1999-11-15 2003-04-15 ティー ガンガル，ハナマラディ 静脈注入のためのブドウ糖およびインスリン含有液体配合物
US6734162B2 (en) 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
US7227033B2 (en) 2002-01-09 2007-06-05 Emisphere Technologies, Inc. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
BR0114799A (pt) 2000-09-06 2003-12-30 Emisphere Tech Inc Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
JP2005504715A (ja) 2000-12-29 2005-02-17 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続放出特性を有する吸入用粒子
US20020141946A1 (en) 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
GB0119665D0 (en) 2001-08-10 2001-10-03 Isis Innovation Conjugates
ATE496064T1 (de) 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US7105539B2 (en) 2002-12-03 2006-09-12 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
AU2003299722A1 (en) 2002-12-17 2004-07-14 Mdrna, Inc. Compositions and methods for enhanced mucosal delivery of y2 receptor-binding peptides and methods for treating and preventing obesity
JP4748791B2 (ja) 2003-02-24 2011-08-17 独立行政法人科学技術振興機構 蛍光性ランタニド錯体
EA200501422A1 (ru) 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
WO2004093833A2 (en) 2003-04-22 2004-11-04 Biodel, Inc. Pad for cleaning and hydrating skin
WO2004111259A2 (en) 2003-06-12 2004-12-23 Perkinelmer Las, Inc. Hydrolytic substrates for an analyte-dependent enzyme activation system
PT103003A (pt) 2003-08-04 2005-02-28 Inst Superior Tecnico Novos inibidores de metalo-enzimas com potencial aplicacao em medicina
CN100372862C (zh) 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
US7658721B2 (en) 2004-01-16 2010-02-09 Biodel Inc. Sublingual drug delivery device
US20080085298A1 (en) 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080096800A1 (en) 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
US7279457B2 (en) 2004-03-12 2007-10-09 Biodel, Inc. Rapid acting drug delivery compositions
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
ATE462427T1 (de) 2004-04-12 2010-04-15 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
FR2914305B1 (fr) 2007-03-29 2009-07-03 Proteins & Peptides Man Dextran fonctionnalise par des amino-acides hydrophobes.
FR2891149B1 (fr) * 2005-09-26 2007-11-30 Biodex Sarl Composition pharmaceutique a action cicatrisante comprenant un derive de dextrane soluble et un facteur de croissance derive des plaquettes.
WO2007038773A1 (en) 2005-09-28 2007-04-05 Biodel, Inc. Self-filling two chamber injectable device
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
JP2007177182A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
PT1969004E (pt) 2005-12-28 2011-11-25 Novo Nordisk As Composições que compreendem uma insulina acilada e zinco e método para criar tais composições
JP2007177185A (ja) 2005-12-28 2007-07-12 Dai Ichi Kogyo Seiyaku Co Ltd 乳化重合用乳化剤、ポリマーエマルションの製造方法及びポリマーエマルション
IL172896A0 (en) 2005-12-29 2006-06-11 Yeda Res & Dev Cxcr4 inhibition
WO2007098058A2 (en) 2006-02-16 2007-08-30 Biodel, Inc. Device for sublingual drug delivery using iontophoresis
US7410045B2 (en) 2006-03-06 2008-08-12 Meadwestvaco Packaging Systems, Llc Offset overhead plunger
JP2009532552A (ja) 2006-04-07 2009-09-10 アドシア 二官能化された多糖類
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
US20120041079A1 (en) 2006-09-26 2012-02-16 Adocia Dextran functionalized by hydrophobic amino acids
EP2081565A2 (en) 2006-10-13 2009-07-29 Reliance Life Sciences Pvt., Ltd. Cinnamic acid, vanillic acid and benzofuran derivatives for use in the treatment of inflammation and cancer
GB0700523D0 (en) 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
FR2919188B1 (fr) 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
WO2009021955A1 (en) * 2007-08-13 2009-02-19 Novo Nordisk A/S Rapid acting insulin analogues
AU2009204309B2 (en) 2008-01-04 2012-11-22 Biodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
FR2927900B1 (fr) 2008-02-27 2010-09-17 Clariant Specialty Fine Chem Procede de preparation d'alpha-aminoacetals optiquement actifs.
JP2009215207A (ja) 2008-03-10 2009-09-24 Hokkaido Univ Ｏ−マンノース型糖鎖結合アミノ酸及びそれを用いた糖ペプチドの製造方法
GB2458473A (en) * 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
KR20110014588A (ko) 2008-04-14 2011-02-11 아도시아 성장인자/양친매성 중합체 복합체, 가용성 양이온 염 및 유기 지지체를 포함하는 골형성 조성물
TWI394580B (zh) 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
US8470574B2 (en) 2008-05-07 2013-06-25 Toyo Boseki Kabushiki Kaisha L-succinylaminoacylase and process for producing L-amino acid using it
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
FR2934999B1 (fr) 2008-08-13 2011-07-29 Adocia Polysaccharides fonctionnalises par des derives du tryptophane
US20100069292A1 (en) * 2008-09-02 2010-03-18 Biodel, Inc. Insulin with a basal release profile
KR20110061639A (ko) 2008-09-26 2011-06-09 아도시아 폴리사카라이드 및 ｈｐｂ로 구성된 복합체
FR2940802A1 (fr) 2008-10-10 2010-07-09 Adocia Complexe entre l'insuline humaine et un polymere amphiphile et utilisation de ce complexe pour la preparation d'une formulation d'insuline humaine rapide.
ES2634454T3 (es) * 2008-10-03 2017-09-27 Glycan Biosciences Llc Conjugados de oligosacárido aniónico
FR2936800B1 (fr) 2008-10-06 2010-12-31 Adocia Polysaccharide comportant des groupes fonctionnels carboxyles substitues par un derive d'alcool hydrophobe
US8759322B2 (en) 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
FR2948573B1 (fr) 2009-07-31 2011-11-18 Adocia Nouvelle forme d'administration de complexes de proteines osteogeniques
JP5232247B2 (ja) 2008-12-11 2013-07-10 東洋紡株式会社 Ｌ−サクシニルアミノアシラーゼ、およびこれを用いたｌ−アミノ酸の製造方法
FR2944448B1 (fr) 2008-12-23 2012-01-13 Adocia Composition pharmaceutique stable comprenant au moins un anticorps monodonal et au moins un polysacharide amphiphile comprenant des substituants derives d'alcools hydrofobes ou d'amines hydrophobes.
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
US20120094902A1 (en) 2009-03-27 2012-04-19 Adocia Fast-acting insulin formulation
FR2943538B1 (fr) * 2009-03-27 2011-05-20 Adocia Formulation a action rapide d'insuline recombinante humaine
FR2980796B1 (fr) 2011-09-30 2014-07-04 Adocia Oligosaccharides fonctionnalises
US9018190B2 (en) 2009-03-27 2015-04-28 Adocia Functionalized oligosaccharides
JP2010235477A (ja) * 2009-03-30 2010-10-21 Asahi Kasei Chemicals Corp 糖エステル化合物
CN101920019B (zh) 2009-06-10 2012-06-06 浙江中医药大学 亲水性聚合物-葛根素特异性缀合的非溶血性缀合物
PL2340033T3 (pl) 2009-06-26 2014-03-31 Novo Nordisk As Preparat zawierający insulinę, nikotynamid i argininę
WO2011059053A1 (ja) 2009-11-13 2011-05-19 東レ株式会社 糖尿病の治療または予防薬
FR2958646B1 (fr) 2010-04-07 2012-05-18 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe.
NZ600764A (en) * 2010-01-22 2013-11-29 Dupont Nutrition Biosci Aps Methods for producing amino-substituted glycolipid compounds
FR2958647B1 (fr) 2010-04-08 2013-08-23 Adocia Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive hydrophobe porte par un spacer au moins trivalent.
CN102834117B (zh) 2010-02-09 2015-11-25 阿道恰公司 通过至少两个由至少三价的间隔物所携带的疏水基团进行官能化的阴离子多糖
JP2011207798A (ja) * 2010-03-29 2011-10-20 Sumitomo Chemical Co Ltd 樹脂用の加工安定化剤、該加工安定化剤を含む樹脂組成物、および樹脂の加工安定性を向上させる方法
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
US8476238B2 (en) 2010-06-29 2013-07-02 Mycomagic Biotechnology Co., Ltd. Uses of an immunomodulatory protein (GMI) from Ganoderma microsporum
JP5806664B2 (ja) 2010-06-30 2015-11-10 積水メディカル株式会社 Ｄ−サクシニラーゼ、およびこれを用いたｄ−アミノ酸の製造方法
US20120178675A1 (en) * 2010-07-07 2012-07-12 Biodel Inc. Compositions And Methods For Modulating The Pharmacokinetics and Pharmacodynamics of Insulin
US8546338B2 (en) 2010-12-08 2013-10-01 Johnson & Johnson Consumer Companies, Inc. Self-assembling hydrogels based on dicephalic peptide amphiphiles
JP2012125162A (ja) 2010-12-13 2012-07-05 Toyama Prefecture チューリッポシド類をチューリッパリン類に変換する酵素活性を有するタンパク質及びそれをコードするポリヌクレオチド
US20120202890A1 (en) 2011-02-08 2012-08-09 Nian Wu Polymer-carbohydrate-lipid conjugates
JP5903298B2 (ja) 2011-03-14 2016-04-13 東洋紡株式会社 Ｎ−サクシニル−ｄｌ−アミノ酸に対する向上されたｄ体選択性を有する改変型ｄ−サクシニラーゼ
US20120295833A1 (en) 2011-05-10 2012-11-22 Adocia Polysaccharides having an adjustable degree of functionalization
WO2012153070A1 (fr) * 2011-05-10 2012-11-15 Adocia Oligosaccharides fonctionnalisés
EP2711077A4 (en) 2011-05-18 2016-07-06 Mitsubishi Gas Chemical Co OXYGEN ABSORBER
AU2012271361B2 (en) 2011-06-17 2017-03-02 Halozyme, Inc. Continuous subcutaneous insulin infusion methods with a hyaluronan degrading enzyme
US9993529B2 (en) 2011-06-17 2018-06-12 Halozyme, Inc. Stable formulations of a hyaluronan-degrading enzyme
BR112014002986A2 (pt) 2011-08-10 2017-06-13 Adocia composição sob a forma de uma solução injetável, e formulação de dose única
US20130231281A1 (en) 2011-11-02 2013-09-05 Adocia Rapid acting insulin formulation comprising an oligosaccharide
WO2013064787A1 (fr) * 2011-11-02 2013-05-10 Adocia Formulation à action rapide d'insuline comprenant un oligosaccharide
LT3130347T (lt) 2011-12-30 2019-10-25 Halozyme Inc Ph20 polipeptido variantai, kompozicijos ir jų panaudojimas
WO2013104861A1 (fr) 2012-01-09 2013-07-18 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150174209A1 (en) 2012-05-25 2015-06-25 Amylin Pharmaceuticals. Llc Insulin-pramlintide compositions and methods for making and using them
EP2920200A1 (fr) 2012-11-13 2015-09-23 Adocia Composes anioniques substitues constitues d'un squelette forme d'un nombre discret d'unites saccharidiques
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
US20140336610A1 (en) 2013-04-09 2014-11-13 Biodel, Inc. Methods and devices for point of use mixing of pharmaceutical formulations
JP2015010075A (ja) 2013-07-01 2015-01-19 学校法人神戸学院 γ−グルタミルシクロトランスフェラーゼ阻害剤
WO2015031709A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations comprising a peptide and a vasodilatory agent
WO2015106269A2 (en) 2014-01-13 2015-07-16 Thermalin Diabetes, Llc Rapid action insulin formulations and pharmaceutical delivery systems
US20150273022A1 (en) 2014-02-10 2015-10-01 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations
TWI685348B (zh) 2014-05-08 2020-02-21 美國禮來大藥廠 速效胰島素組合物
FR3020952B1 (fr) 2014-05-14 2017-09-08 Adocia Formulation a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
FR3043557B1 (fr) 2015-11-16 2019-05-31 Adocia Composition a action rapide d'insuline comprenant un citrate substitue
WO2018153506A1 (en) 2017-02-22 2018-08-30 Adocia Fast-acting insulin composition comprising a citric acid salt

Also Published As

Publication number Publication date
EP3332810A1 (fr) 2018-06-13
AU2018208773B2 (en) 2020-08-06
KR20150082640A (ko) 2015-07-15
JP7332139B2 (ja) 2023-08-23
WO2014076423A1 (fr) 2014-05-22
CN104902922B (zh) 2017-12-12
SA515360428B1 (ar) 2017-12-05
EA034393B1 (ru) 2020-02-03
US20140378373A2 (en) 2014-12-25
HK1213493A1 (zh) 2016-07-08
EP3332810B1 (fr) 2021-01-13
US20200113976A1 (en) 2020-04-16
US10583175B2 (en) 2020-03-10
CA2889552C (fr) 2023-10-10
US20210060133A1 (en) 2021-03-04
ZA201503293B (en) 2022-05-25
HK1252137A1 (zh) 2019-05-17
MX2015005786A (es) 2015-09-23
IL238446B (en) 2020-04-30
EP2919804A1 (fr) 2015-09-23
JP2015537024A (ja) 2015-12-24
KR20210008934A (ko) 2021-01-25
US20140142034A1 (en) 2014-05-22
KR102367083B1 (ko) 2022-02-24
AU2018208773A1 (en) 2018-08-16
US10646551B2 (en) 2020-05-12
JP6322642B2 (ja) 2018-05-09
JP2023099873A (ja) 2023-07-13
ZA202003132B (en) 2023-04-26
PL2919804T3 (pl) 2018-07-31
BR112015010799B1 (pt) 2023-01-17
AU2013346624A1 (en) 2015-05-14
US9700599B2 (en) 2017-07-11
US10881716B2 (en) 2021-01-05
EA201590944A1 (ru) 2016-05-31
CA2889552A1 (fr) 2014-05-22
CN107952065A (zh) 2018-04-24
JP2019142955A (ja) 2019-08-29
CN104902922A (zh) 2015-09-09
US20170143835A1 (en) 2017-05-25
KR20200084927A (ko) 2020-07-13
ES2670969T3 (es) 2018-06-04
US20200237877A1 (en) 2020-07-30
MX360107B (es) 2018-10-23
IL238446A0 (en) 2015-06-30
US20170368146A1 (en) 2017-12-28
IL274077A (en) 2020-06-30
BR112015010799A2 (enExample) 2017-08-15
KR102205512B1 (ko) 2021-01-20
MX377292B (es) 2025-03-07
US11324808B2 (en) 2022-05-10
JP2018021075A (ja) 2018-02-08
EP2919804B1 (fr) 2018-01-31
DK2919804T3 (en) 2018-05-14

Similar Documents

Publication Publication Date Title
US10881716B2 (en) Rapid-acting insulin formulation comprising a substituted anionic compound
US9492467B2 (en) Rapid-acting insulin formulation comprising an oligosaccharide
EP2773675B1 (fr) Formulation à action rapide d'insuline comprenant un oligosaccharide
JP2012521980A (ja) 即効性インシュリン製剤
HK1213493B (en) Quick-acting insulin formulation including a substituted anionic compound
FR2997857A1 (fr) Formulation a action rapide d'insuline comprenant un compose anionique substitue

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ SOULA, OLIVIER; SOULA, GERARD; DAUTY, EMMANUEL AND CHARVET, RICHARD

FGA Letters patent sealed or granted (standard patent)